Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer

2009 ◽  
Vol 48 (7) ◽  
pp. 642-647 ◽  
Author(s):  
Nazanin Mostafaie ◽  
Enikö Kállay ◽  
Elisabeth Sauerzapf ◽  
Elisabeth Bonner ◽  
Stefan Kriwanek ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Estrogen Receptor ◽  
Circadian Clock ◽  
Clock Gene ◽  
Estrogen Receptor Beta ◽  
Human Colorectal Cancer ◽  
Circadian Clock Gene ◽  
Receptor Beta

scholarly journals Colitis‐induced colorectal cancer and intestinal epithelial estrogen receptor beta impact gut microbiota diversity

2019 ◽  
Vol 144 (12) ◽  
pp. 3086-3098 ◽  
Author(s):  
Ahmed Ibrahim ◽  
Luisa W. Hugerth ◽  
Linnea Hases ◽  
Ashish Saxena ◽  
Maike Seifert ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Estrogen Receptor ◽  
Gut Microbiota ◽  
Estrogen Receptor Beta ◽  
Intestinal Epithelial ◽  
Microbiota Diversity ◽  
Receptor Beta

scholarly journals Estrogen receptor beta as target for colorectal cancer prevention

2016 ◽  
Vol 372 (1) ◽  
pp. 48-56 ◽  
Author(s):  
Cecilia Williams ◽  
Alfredo DiLeo ◽  
Yaron Niv ◽  
Jan-Åke Gustafsson
Keyword(s):  
Colorectal Cancer ◽  
Estrogen Receptor ◽  
Cancer Prevention ◽  
Estrogen Receptor Beta ◽  
Colorectal Cancer Prevention ◽  
Receptor Beta

Estrogen receptor beta as a marker of tumor progression and prognosis in colorectal cancer.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e14605-e14605
Author(s):  
Paulo Roberto Stevanato Filho ◽  
Samuel Aguiar ◽  
Maria D. Begnami ◽  
Fabio Oliveira Ferreira ◽  
Wilson Toshihiko Nakagawa ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Estrogen Receptor ◽  
Tumor Progression ◽  
Estrogen Receptor Beta ◽  
Receptor Beta

Circadian clock gene PER1 mutations in colorectal cancer (CRC).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 12106-12106 ◽  
Author(s):  
Francesca Battaglin ◽  
Joanne Xiu ◽  
Michelle Winerip ◽  
Richard M. Goldberg ◽  
Philip Agop Philip ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Circadian Clock ◽  
Clock Gene ◽  
Circadian Clock Gene

scholarly journals Circadian Clock Gene CRY2 Degradation Is Involved in Chemoresistance of Colorectal Cancer

2015 ◽  
Vol 14 (6) ◽  
pp. 1476-1487 ◽  
Author(s):  
Lekun Fang ◽  
Zihuan Yang ◽  
Junyi Zhou ◽  
Jung-Yu Tung ◽  
Chwan-Deng Hsiao ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Circadian Clock ◽  
Clock Gene ◽  
Circadian Clock Gene

Clinicopathological Significance of the Expression of Estrogen Receptor-beta and Vascular Endothelial Growth Factor-A in Colorectal Cancer

2012 ◽  
Vol 78 (12) ◽  
pp. 1376-1382 ◽  
Author(s):  
Deepa Taggarshe ◽  
Catherine Lobocki ◽  
Boris Silberberg ◽  
Alasdair Mckendrick ◽  
Vijay K. Mittal
Keyword(s):  
Colorectal Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Estrogen Receptor ◽  
Estrogen Receptor Beta ◽  
Normal Mucosa ◽  
Vascular Endothelial ◽  
Malignant Cells ◽  
Clinicopathological Significance ◽  
Endothelial Growth Factor ◽  
Receptor Beta

Estrogen-receptor-beta (ERβ), progesterone receptor (PR) and vascular endothelial growth factor (VEGF-A) have been implicated in colorectal cancer. However, the clinicopathological significance of any expression of these markers remains unclear. Immunohistochemical assays of ERα, ERβ, PR, and VEGF-A were performed on 72 colorectal cancer cases. Normal mucosa from the same cases was assessed as a control. The correlation of presence of these markers with clinicopathological features and survival was determined. ERα and PR were not expressed in tumors. Forty-one of 53 (77.4%) cases of normal mucosa showed strong ERβ expression compared with weak expression in 32 of 72 (44.4%) of malignant cells. A significant decrease in ERβ expression from normal mucosa to tumor was found in females ( P = 0.007) but not in males ( P = 0.149). VEGF-A was expressed strongly in malignant cells in 64 of 72 (89%) cases. No association was found between ERβ or VEGF-A expression and tumor grade, angiolymphatic involvement, stage, disease-free survival, or overall survival. Colorectal cancers do not express ERα or PR. ERβ may have a protective role, especially in females. VEGF-A may have a role in tumorigenesis. Nevertheless, ERβ and VEGF-A cannot be used as prognostic markers.

Polymorphisms in estrogen receptor beta, interleukin-8, and interleukin-8 receptor associated with clinical outcome in metastatic colorectal cancer (mCRC) patients treated with 5-fluorouracil/oxaliplatin

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4130-4130
Author(s):  
R. D. Ladner ◽  
M. A. Gordon ◽  
W. Zhang ◽  
D. Yang ◽  
F. Nagashima ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Estrogen Receptor ◽  
Clinical Outcome ◽  
Tumor Progression ◽  
Sex Hormones ◽  
Tumor Response ◽  
Estrogen Receptor Beta ◽  
Interleukin 8 ◽  
Receptor Beta ◽  
Time To Tumor Progression

4130 Background: Many factors contribute to the progression of colorectal cancer and to chemoresistance. Two factors that have recently gained attention are angiogenesis and sex hormones. Interleukin-8 and its receptors play a critical role in angiogenesis, and polymorphisms in these genes have previously been reported to predict clinical outcome and resistance to therapy in a variety of cancer types. In addition, gender and the subsequent varied levels of sex hormones between males and females may also have an impact on colorectal cancer progression. Sex hormones such as estrogen exert their effects on the cell by binding to steroid receptors such as estrogen receptor beta (ER-β). It is known that ER-β is predominantly expressed in the colon, and that differential expression of this gene is predictive of clinical outcome. Therefore, functional polymorphisms within ER-β, IL-8, and the IL-8 receptors may prove to be molecular markers for predicting clinical outcome in colorectal cancer patients. Methods: 173 patients were enrolled in this phase II study. 152 patients were evaluable for genotyping and statistical analysis. There were 74 females and 78 males, and median age was 60 (range 25–87). The dose of oxaliplatin was 130mg/m2 every 3 weeks and 5-FU was 200mg/m2/day CI for 10 weeks followed by 2 weeks rest. Polymorphisms in estrogen receptor beta, IL-8, and CXCR2 (IL-8 receptor) were tested by PCR. Results: Median follow-up was 18.6 months, response rate 19%, median time to tumor progression 4.2 months and median survival 10.3 months. IL-8 T251A polymorphism was predictive of time to tumor progression (p=0.04, log-rank test). ER-β CA repeat polymorphism was predictive of tumor response as well as time to tumor progression (p=0.015, p=0.012, respectively). ER-β A730G SNP was also predictive of time to tumor progression (p=0.03). Polymorphism in CXCR2 was predictive of tumor response (p=0.034). Conclusions: Our results suggest that polymorphisms within IL-8, CXCR2, and ER-β may affect the progression of colorectal cancer and subsequent clinical outcome. These results highlight the importance of angiogenesis and hormone levels in colorectal cancer. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document